Sign inJoin waitlistJoin the waitlist

AH

Alan Ho

Chief, Head and Neck Oncology Service · New York Presbyterian Hospital

Credentials: · · · ·

History

Head and Neck Oncology Service Division · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Memorial Sloan Kettering Cancer Center
2006–2008
NewYork-Presbyterian
2003–2006
Washington University School of Medicine
1999–2003

Research

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics · 2019 · 3,156 citations
OncoKB: A Precision Oncology Knowledge Base
JCO Precision Oncology · 2017 · 2,318 citations
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer
New England Journal of Medicine · 2013 · First of 17 authors · 633 citations

ES
Eric Sherman
57 papers
David Pfister
45 papers
NL
Nancy Lee
40 papers
NK
Nora Katabi
39 papers
Richard Wong
39 papers
LD
Lara Dunn
37 papers · 5 as a fellow
Nadeem Riaz
35 papers · 2 as a resident
RG
Ronald Ghossein
31 papers
Ian Ganly
28 papers
Luc Morris
28 papers
Sean McBride
25 papers
James Fagin
23 papers

Grants

Phase II Trial of Avutometinib Plus Defactinib in RAF Dimer-Driven Thyroid Cancers
Food and Drug Administration · R01
Contact PI · $602K · Sloan-Kettering Inst Can Research
2024–2028
Improving Efficacy of Radioiodine Treatment of Thyroid Cancer
National Cancer Institute · R01
PI · $2.3M · Sloan-Kettering Inst Can Research
2021–2026
Identifying and Targeting Neoantigens in Aggressive Salivary Carcinomas
National Institute of Dental and Craniofacial Research · R01
PI · $2.8M · Sloan-Kettering Inst Can Research
2018–2024
Targeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid Cancer
National Cancer Institute · R01
Contact PI · $1.7M · Sloan-Kettering Inst Can Research
2015–2020

Clinical trials

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2025–2027
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2023–2027
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
Principal investigator · Active not recruiting · Phase 2
National Cancer Institute (NCI)
2023–2026
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Principal investigator · Recruiting · Phase 2
NRG Oncology
2023–2032